# Sex-based differences in clearance of chronic *Plasmodium falciparum* infection

- 3
- 4 Jessica Briggs, M.D.<sup>1\*</sup>, Noam Teyssier, B.S.<sup>1</sup>, Joaniter I. Nankabirwa, Ph.D.<sup>2,3</sup>, John Rek, MSc<sub>2</sub>,
- 5 Prasanna Jagannathan, M.D.<sup>4</sup>, Emmanuel Arinatiwe, MPH<sup>2,9</sup>, Teun Bousema, Ph.D.<sup>5, 6</sup>, Chris
- 6 Drakeley, Ph.D.<sup>6</sup>, Margaret Murray, M.S.<sup>4</sup>, Emily Crawford, Ph.D.<sup>7</sup>, Nicholas Hathaway, M.D.<sup>8</sup>,
- 7 Sarah G. Staedke, Ph.D.<sup>9</sup>, David Smith, Ph.D.<sup>10</sup>, Phillip J. Rosenthal, M.D.<sup>1</sup>, Moses Kamya,
- 8 Ph.D.<sup>2,3</sup>, Grant Dorsey, M.D.<sup>1</sup>, Isabel Rodriguez-Barraquer, M.D.<sup>1</sup>\*\*,
- 9 Bryan Greenhouse, M.D.<sup>1</sup>\*\*
- 10 \*\*co-senior authors
- 11
- 12 <sup>1</sup> Department of Medicine, University of California San Francisco, San Francisco, CA
- 13 <sup>2</sup>Infectious Diseases Research Collaboration, Kampala, Uganda
- <sup>3</sup> Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
- 15 <sup>4</sup> Department of Medicine, Stanford University, Palo Alto, CA
- <sup>5</sup> Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen,
- 17 the Netherlands
- <sup>6</sup> Department of Immunology and Infection, London School of Hygiene and Tropical Medicine,
- 19 London, UK
- 20 <sup>7</sup> Chan-Zuckerberg Biohub, San Francisco, CA
- 21 <sup>8</sup> Department of Medicine, University of Massachusetts, Amherst, MA
- <sup>9</sup> Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK
- 23 <sup>10</sup>Institute for Health Metrics & Evaluation, University of Washington, Seattle, WA
- 24
- 25
- 26
- 27

28

# 29 \*Corresponding Author: Jessica Briggs, Rm 525 Building 3, Zuckerberg San Francisco

- 30 General Hospital, San Francisco, CA. Email: jessica.briggs@ucsf.edu
- 31
- 32 Author Contributions: M.K, G.D., I.R-B., P.J., and B.G designed and lead the project. J.B.
- 33 performed experiments, analyzed the sequencing data, performed statistical analyses, and
- drafted the paper. N.T. was responsible for bioinformatics programming and data analysis.
- J.I.N., J.R, and E.A. led the parent study in Uganda. E.C. and N.H. provided technical support
- 36 for sequencing and bioinformatics analysis. M.M., C.D., T.B., S.G.S, D.S., and P.J.R. edited the
- 37 manuscript.
- 38 Key words: malaria, asymptomatic infection, force of infection, duration of infection,
- 39 genotyping, sex-based differences

#### 40 Abstract

41

Background: Multiple studies have reported a higher prevalence of malaria infection in males
compared to females. However, it remains unknown whether this is due to differences in
behavioral factors or biological sex playing a direct role in the host response to the malaria
parasite.

46 **Methods and Findings**: To test the hypothesis that sex-based differences in host-parasite

47 interactions affect the epidemiology of malaria, we intensively followed a cohort of individuals

48 living in a malaria endemic area of eastern Uganda. By performing frequent sampling,

49 ultrasensitive quantitative PCR (qPCR), and amplicon deep sequencing, we followed P.

50 *falciparum* infections over time to estimate both force of infection (FOI) and rate of clearance by

51 sex. Prevalence of malaria infection by qPCR was 14.4% in males versus 9.2% in females

52 (difference 5.2%, 95% confidence interval [CI] 3.8% to 6.5%). There was no evidence of

53 differences in behavioral risk factors, incidence of malaria, or FOI by sex. In contrast, females

54 cleared asymptomatic infections at a faster rate than males (hazard ratio [HR] = 1.82, 95% CI

55 1.20 to 2.75 by clone and HR = 2.07, 95% CI 1.24 to 3.47 by infection event) in multivariate

56 models adjusted for age, timing of infection onset, and parasite density.

57 Conclusions: In this study, differences in *P. falciparum* prevalence between males and females
58 observed in endemic settings were driven by faster clearance rates in females and not by
59 increased infection rates in males. These findings implicate biological sex-based differences as
60 an important factor in the host response to this globally important pathogen.

61

# 63 Introduction

64	Chronic infection with Plasmodium falciparum, the most common and fatal malaria
65	parasite, can lead to morbidity for those infected and contribute to ongoing transmission 1-
66	4. Multiple studies performed in different contexts have demonstrated that, excepting impacts of
67	pregnancy, a greater proportion of males than females in endemic settings carry malaria
68	parasites in their blood <sub>5-7</sub> . It has often been postulated that these differences in parasite
69	prevalence stem from an increased risk of males acquiring infection due to socio-behavioral
70	factors <sub>6,8-10</sub> . However, biological sex itself has been demonstrated to affect responses to other
71	pathogens, and thus an alternative hypothesis is that the sexes have different responses to the
72	malaria parasite once infected11-14.

73 Estimating the host response to *P. falciparum* infection requires close follow up of 74 infected individuals, sensitive detection of parasites, and the ability to distinguish superinfection, 75 which is common in endemic areas, from persistent infection. To test the hypothesis that sex-76 based differences in host-parasite interactions affect the epidemiology of malaria, we intensively 77 followed a representative cohort of individuals living in a malaria endemic area of eastern Uganda. By performing frequent sampling, ultrasensitive qPCR, and amplicon deep sequencing, 78 79 we were able to accurately detect the onset of new infections and follow them over time to 80 estimate their duration. Using these data, we show that females cleared their infections more 81 rapidly than males, implicating biological sex-based differences as important in the host 82 response to this globally important pathogen.

### 83 Methods

#### 84 Study setting and population-level malaria control interventions

85 This cohort study was carried out in Nagongera sub-county, Tororo district, eastern

Uganda. Nagongera district is historically a high malaria transmission area; however, 7 rounds
of indoor residual spraying (IRS) from 2014-2019 have resulted in a significant decline in the
burden of malaria as previously described<sub>15</sub>.

89

#### 90 Study design, enrollment, and follow-up

91 All members of 80 randomly selected households with at least two children were 92 enrolled in October 2017 using a list generated by enumerating and mapping all households in 93 Nagongera sub-county. The cohort was dynamic such that residents joining the household were 94 enrolled and residents leaving the household were withdrawn. Data for this analysis was collected from October 1st, 2017 through March 31st, 2019. Participants were followed at a 95 designated study clinic open daily from 8 AM to 5 PM. Participants were encouraged to seek all 96 97 medical care at the study clinic and avoid the use of antimalarial medications outside of the 98 study. Routine visits were conducted every 28 days and included a standardized clinical 99 evaluation, assessment of overnight travel outside of Nagongera sub-county, and collection of 100 blood by phlebotomy for detection of malaria parasites by microscopy and molecular studies. 101 Participants with fever (>38.0°C tympanic) or history of fever in the previous 24 hours had a 102 thick blood smear read urgently. If the smear was positive, the patient was diagnosed with 103 malaria and treated with artemether-lumefantrine. Study participants were visited at home every 104 2 weeks to assess use of long-lasting insecticidal nets (LLINs) the previous night.

105

#### 106 Laboratory methods

Blood smears were performed as previously described  $_{15}$ . For qPCR and genotyping, we collected 200 µL of blood at enrollment, at each routine visit, and at the time of malaria diagnosis. DNA was extracted using the PureLink Genomic DNA Mini Kit (Invitrogen) and parasitemia measured using an ultrasensitive qPCR assay<sub>16</sub>. Samples with a parasite density >= 0.1 parasites/µL blood were genotyped via amplicon deep-sequencing. All samples positive

- for asexual parasites by microscopy but negative for *P. falciparum* by qPCR were tested for the
- 113 presence of non-falciparum species using nested PCR.17
- 114
- 115 Sequencing library preparation
- 116 Hemi-nested PCR was used to amplify a 236 base-pair segment of apical membrane
- antigen 1 (AMA-1) using a published protocol<sub>18</sub>, with modifications (Supplemental Appendix).
- 118 Samples were amplified in duplicate, indexed, pooled, and purified by bead cleaning.
- 119 Sequencing was performed on an Illumina MiSeq platform (250bp paired-end).
- 120

#### 121 Bioinformatics methods

- 122 Data extraction, processing, and haplotype clustering were performed using SeekDeep 19,
- 123 followed by additional filtering<sub>20</sub>. **Supplemental Figure 1** shows the full bioinformatics
- 124 workflow.
- 125

#### 126 Data analysis

A clone was defined as a genetically identical group of parasites. A baseline infection was defined as an infection detected in the first 60 days of observation. New infections were defined as a new clone or group of clones detected in an individual after day 60. To account for the fact that a clone might be missed in a single sample due to fluctuations in parasite density<sub>21-</sub> we allowed 3 "skips" in detection and classified an infection as cleared only if it was not identified in 4 contiguous samples from routine visits. Additional details are found in

133 Supplemental Table 1.

Because polyclonal infections can occur due to co-infection (one mosquito bite transmitting multiple clones) or superinfection (multiple bites), we analyzed the data both by clone and by infection event. For analysis by clone, the appearance of each unique clone was counted as a new infection and disappearance as a clearance event. For analysis by infection

138 event, any new clones seen within 3 visits of the date of the first newly detected clone(s) were 139 grouped together and considered one new "infection event." Clearance of infection for these 140 events required that all clones in the group be absent for 4 routine visits. 141 Data analysis was conducted in R<sub>25</sub> and Python<sub>26</sub>. Comparisons of proportions were 142 made using Poisson regression with generalized estimating equations to adjust for repeated 143 measures. Comparison of parasite density by sex was made using linear regression with 144 generalized estimating equations to adjust for repeated measures. Force of infection (FOI) was 145 calculated by dividing the number of new infections, including malaria episodes, by person time. 146 Comparisons of incidence measures were made using negative binomial regression. Hazards 147 for clearance of untreated, asymptomatic infections were estimated using time-to-event models 148 (shared frailty models fit using R package "frailtypack," version 2.12.2)27,28. These models 149 assumed a constant hazard of clearance and included random effects to account for repeated 150 measures in individuals. Parasite density was included in the model as a time-varying covariate. 151 Duration of infection in days was calculated as 1/adjusted hazard. 152 Results 153 154 155 Cohort participants and *P. falciparum* infections 156 This analysis involved data from 477 children and adults (233 males and 244 females) 157 that were followed for a total of 1339 person-years (Table 1). 158 159 160 161

**Table 1. Behavioral risk factors for malaria infection and measures of malaria burden in study population, stratified by age** 

**and sex** 


	Age and gender categories							
Metric	All		< 5 years old		5-15 years old		16 years and older	
	Male	Female	Male	Female	Male	Female	Male	Female
Number of participants, n	233	244	73	84	101	71	59	89
Slept under LLIN the previous night	54.7%	56.3%	54.1%	56.2%	47.9%	47.8%	63.7%	64.3%
Person-years of follow up	324.2	345.4	87.3	96.7	152.6	118.5	84.22	130.1
Number of overnight trips, (incidence*)	44 (0.14)	107 (0.31)	21 (0.24)	19 (0.20)	9 (0.06)	10 (0.08)	14 (0.17)	78 (0.60)
Episodes of malaria**, (incidence*)	11 (0.03)	13 (0.04)	5 (0.06)	2 (0.02)	5 (0.03)	9 (0.08)	1 (0.01)	2 (0.02)
Number of routine visits, n	4,319	4,583	1164	1293	2034	1568	1121	1722
Prevalence of parasitemia by microscopy***	2.9%	1.4%	1.8%	1.1%	4.4%	2.7%	1.3%	0.5%
Prevalence of parasitemia by qPCR	14.4%	9.2%	5.8%	3.7%	17.0%	15.3%	18.5%	7.7%

166 \*per person-year

167 \*\*Malaria includes 1 episode (female, < 5 years old), due to non-falciparum species (*P. malariae*)

168 \*\*\*Parasitemia by light microscopy includes 1 episode (female, 5-15 years old) due to non-falciparum species (*P. ovale*)

- 170 149 of 477 participants (31.2%) included in the analysis had at least one *P. falciparum* infection
- 171 detected (Figure 1).
- 172 Figure 1. Study design.
- 173



- 174
- 114 participants had 822 successfully genotyped samples and had infections characterized by
  clone and by infection event. We achieved a read count of >10,000 for 92% of genotyped
  samples, identifying 45 unique AMA-1 haplotypes in our population (frequencies and sequences
  in Supplemental Table 2). 35 samples had very low-density infections (< 1 parasite/µL) that</li>
  could not be genotyped and had infections characterized at the event level only.

#### 181 Behavioral malaria risk factors and measures of malaria burden

- 182 There was no difference in reported rates of LLIN use the previous night by sex (Table
- 183 1). Women over the age of 16 traveled overnight outside of the study area more than men
- 184 (incidence rate ratio [IRR] for females vs. males = 3.39, 95% confidence interval [CI] 1.92 to

185 5.99), a potential risk factor for malaria exposure. In this region receiving regular rounds of IRS, 186 the incidence of symptomatic malaria was low in all age categories, and there was no evidence 187 of a difference in incidence of symptomatic malaria by sex overall (IRR for females vs. males = 188 1.14, 95% CI 0.37 to 3.51) or when adjusted for age (IRR = 1.24, 95% CI 0.37 to 4.13). In contrast, prevalence of *P. falciparum* parasitemia by microscopy was 2.9% in males compared 189 190 to 1.4% in females across all age categories (difference of proportions 1.5%, 95% CI 0.87% to 191 2.1%), with relative differences in prevalence most pronounced in the oldest age group. Similar 192 findings were seen when prevalence was assessed by ultrasensitive qPCR (14.4% in males vs. 193 9.2% in females, 95% CI for difference of proportions 3.8% to 6.5%), again with the largest 194 differences seen in the oldest age group. There was no evidence for differences in parasite 195 density as determined by qPCR between males and females after adjusting for age as a 196 continuous variable (p = 0.47).

197

#### **Force of infection by age and sex**

To determine whether higher infection prevalence in males was due to an increased rate of infection, we used longitudinal genotyping to calculate the force of infection (FOI, number of new blood stage infections per unit time). Overall, the FOI was low, with new infections occurring on average less than once every 5 years (Table 2).

# 203 Table 2. Molecular force of infection (FOI) by clone and by infection event, stratified by age and sex

204
-----

Molecular force of	Sex	Age category					
infection (FOI)		All	< 5 years	5-15 years	16 years or older		
	All	0.17 (0.13-0.23)	0.14 (0.07-0.23)	0.18 (0.08-0.39)	0.19 (0.09-0.44)		
By clone, ppy* (95% Cl)	Male	0.18 (0.12-0.28)	0.16 (0.06-0.45)	0.19 (0.12-0.33)	0.21 (0.09-0.48)		
	Female	0.16 (0.09-0.30)	0.11 (0.02-0.49)	0.18 (0.08-0.42)	0.18 (0.06-0.54)		
	All	0.14 (0.11-0.18)	0.09 (0.06-0.16)	0.16 (0.08-0.30)	0.16 (0.08-0.32)		
By event, ppy* (95% Cl)	Male	0.16 (0.11-0.22)	0.13 (0.07-0.26)	0.18 (0.12-0.27)	0.15 (0.07-0.15)		
	Female	0.13 (0.08-0.21)	0.06 (0.02-0.19)	0.14 (0.07-0.27)	0.18 (0.07-0.43)		

205 \*per person-year

207 There was no evidence for a significant difference in FOI by sex overall (IRR for females vs. 208 males = 0.88, 95% CI 0.48 to 1.62 by clone and IRR = 0.83, 95% CI 0.52 to 1.33 by infection 209 event). There was also no evidence for a significant difference in FOI by sex when adjusted for 210 age category (IRR = 0.84, 95% CI 0.45 to 1.56 by clone and IRR = 0.79, 95% CI 0.49 to 1.28 by 211 infection event). 212 213 Rate of clearance of infection and duration of infection by sex 214 Since females had a lower prevalence of infection but similar rate of acquiring infections 215 compared to males, we evaluated whether there was a difference between sexes in the rate at 216 which infections were cleared. Unadjusted hazard ratios for clearing infecting clones showed 217 that asymptomatic infections cleared naturally (*i.e.*, when not treated by antimalarials) at nearly 218 twice the rate in females vs. males (hazard ratio (HR) 1.92, 95 % CI 1.19 to 3.11, Table 3). In 219 addition, new infections cleared faster than baseline infections and monoclonal infections 220 cleared faster than polyclonal infections. Unadjusted hazard ratios for clearance of infection 221 events (as opposed to clones) also showed faster clearance in females vs. males (HR = 2.30,

222 95% CI 1.20 to 4.42).

# 223 Table 3. Hazard ratios for rates of clearance of infection, by clone and by infection event

ZZ4
-----

Catagorias	Hazard ratio by	clone (95% Cl)	Hazard ratio by infection event (95% CI)		
Categories	Unadjusted	Adjusted	Unadjusted	Adjusted	
Male	ref	ref	ref	ref	
Female	1.92 (1.19-3.11)	1.82 (1.20 – 2.75)	2.30 (1.20 – 4.42)	2.07 (1.24 – 3.47)	
16 years or greater	ref	ref	ref	ref	
5-15 years	0.66 (0.39 – 1.10)	0.81 (0.49 – 1.36)	0.82 (0.39 – 1.74)	1.27 (0.72 – 2.25)	
< 5 years	1.64 (0.79 – 3.41)	1.55 (0.76 – 3.17)	2.01 (0.80 – 5.00)	1.75 (0.87 – 3.53)	
Polyclonal (COI > 1)	ref		ref		
Monoclonal (COI = 1)	1.63 (1.03 – 2.57)		0.95 (0.38 – 2.34)		
Present at baseline	ref	ref	ref	ref	
New infection	1.94 (1.22 – 3.07)	1.75 (1.05 – 2.94)	4.66 (2.58 – 8.42)	4.32 (2.59 – 7.20)	
	0.85 (0.69 – 1.06)	0.81 (0.65 – 1.00)	0.41 (0.32 – 0.51)	0.44 (0.35 – 0.54)	
	Female 16 years or greater 5-15 years < 5 years Polyclonal (COI > 1) Monoclonal (COI = 1) Present at baseline	CategoriesUnadjustedMalerefFemale $1.92 (1.19-3.11)$ 16 years or greaterref5-15 years $0.66 (0.39 - 1.10)$ < 5 years	Unadjusted         Adjusted           Male         ref         ref           Female         1.92 (1.19-3.11)         1.82 (1.20 – 2.75)           16 years or greater         ref         ref           5-15 years         0.66 (0.39 – 1.10)         0.81 (0.49 – 1.36)           < 5 years	Categories         Unadjusted         Adjusted         Unadjusted           Male         ref         ref         ref           Female         1.92 (1.19-3.11)         1.82 (1.20 - 2.75)         2.30 (1.20 - 4.42)           16 years or greater         ref         ref         ref           5-15 years         0.66 (0.39 - 1.10)         0.81 (0.49 - 1.36)         0.82 (0.39 - 1.74)           < 5 years	


<sup>225</sup> \*Increasing parasite density (log10) in parasites/microliter, as measured by qPCR

226

228	Results were similar in multivariate models including age, gender, the period during
229	which the infection was first observed, and parasite density, demonstrating faster clearance in
230	females vs. males (HR =1.82, 95% CI 1.20 to 2.75 by clone and HR =2.07, 95% CI 1.24 to 3.47
231	by infection event). In both adjusted models, new infections cleared faster than baseline
232	infections. Higher parasite densities were associated with slower clearance by clone and by
233	infection event, but the effect size was larger when data were analyzed by infection event (HR =
234	0.44, 95% CI 0.35 to 0.54). There was no evidence for interaction between age and sex in either
235	adjusted model.
236	We next estimated durations of asymptomatic infection by age and sex using results
237	from a model that included these covariates (Figure 2). Durations of infection ranged from 103
238	days to 447 days by clone, and from 87 to 536 days by infection event. Males had a longer
239	duration of infection across all age categories. Children aged 5-15 years had the longest
240	duration of infection, followed by adults. Therefore, overall, males aged 5-15 years had the
241	longest estimated duration of infection by either clone (447 days) or infection event (526 days).
242	
243	
244	
245	
246 247	
247	
249	
250	
251	
252	
253	
254	
255	
256	
257	
258 259	
259 260	
200	



- 262
- 263
- 264



265 Estimated duration of infection in days,

- 266 calculated by adjusting the point estimate of the
- baseline hazard by coefficients of the sex- and
- age-adjusted model. Error bars represent
- 268 standard errors of duration obtained from
- variance in the model coefficients. Point
- 269 estimates of duration are labeled (\*).
- 270

# 271 Discussion

- 272 Previous studies have reported a higher prevalence of malaria infection in males
- 273 compared to females, with the difference often ascribed to differences in exposure 5-7. By closely
- 274 following a cohort of children and adults and genotyping every detected infection with sensitive
- amplicon deep-sequencing, we were able to estimate both the rate of infection (FOI) and
- 276 duration of infection and to compare these measures by sex. We found that lower prevalence in

females did not appear to be due to lower rates of infection but rather due to faster clearance of
infections. To our knowledge, this is the first study to report a sex-based difference in the
duration of malaria infection.

280 Many prior studies of malaria incidence and/or prevalence that evaluated associations 281 with sex in late childhood, adolescence and adulthood have found a male bias in the observed 282 measure of burden<sub>5-8,29</sub>. Overall, these studies consistently suggest that males exhibit higher 283 incidence and/or prevalence of malaria that begins during late childhood, persisting through 284 puberty and the majority of adulthood (excepting the years when pregnancy puts women at 285 higher risk). One possible explanation put forward for the sex-specific difference in burden has 286 been that males are more frequently bitten by malaria-carrying mosquitos due to behavioral 287 differences such as working outside, not sleeping under a net, or traveling for work<sub>6.8-10</sub>. In our 288 study, however, there were no significant differences in malaria incidence or FOI by sex. We 289 also saw no evidence of behavioral trends that would result in more infections in males; in fact, 290 older women in our study did most of the traveling outside the study area (an area of low 291 transmission compared to surrounding areas). We did not assess work habits as part of our 292 study questionnaire, but the fact that we observe similar patterns in prevalence by sex in all age 293 categories makes this a less likely explanation.

294 Very few studies have been conducted to explore immunological differences between 295 males and females in their response to the malaria parasite. The Garki project found that 296 females had higher levels of antibodies against *P. falciparum* compared to men<sub>5</sub>. Additionally, 297 the RTS,S vaccine is associated with higher all-cause mortality in girls compared to boys, and a 298 trend toward higher risk of fatal malaria was noted in vaccinated girls compared to boys<sub>30</sub>. 299 Hormonal differences may play a role; studies in mice show that testosterone appears to 300 downregulate the immune response to malaria<sub>31,32</sub>. More studies are needed to elucidate the 301 relationship between sex-based biological differences between males and females and their 302 effects on the development of effective antimalarial immunity.

303 Of the variables we evaluated in addition to sex, baseline infection status and parasite 304 density were associated with the rate of clearance of infection. Infections that were already 305 present at the beginning of the study may have been a non-random selection of well-established 306 asymptomatic infections that were present at baseline at a higher frequency than average 307 because they had a fundamentally different trajectory than newly established asymptomatic 308 infections. Higher parasite densities were also associated with slower clearance of infection in 309 both adjusted models, but the effect was most pronounced when the data were analyzed by 310 infection event. This may be because low-density infections that we were unable to successfully 311 genotype were only included in the infection event analysis, and these events tended to have 312 short durations. The inclusion of parasite density in our multivariate models did not meaningfully 313 alter associations between sex and duration of infection, providing evidence that the sex-based 314 differences in duration were not mediated primarily by differences in parasite density in our 315 cohort.

#### 317 References

- 319 1. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability,
- 320 transmissibility and public health relevance. Nat Rev Microbiol. 2014;12(12):833–840.
- 321 2. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. Factors determining
- 322 the occurrence of submicroscopic malaria infections and their relevance for control.
- 323 Nature Communications. 2012 Dec 4;3(1):1–9.
- 324 3. Tadesse FG, Slater HC, Chali W, et al. The Relative Contribution of Symptomatic and
- 325 Asymptomatic Plasmodium vivax and Plasmodium falciparum Infections to the Infectious
- Reservoir in a Low-Endemic Setting in Ethiopia. Clin Infect Dis. 2018 01;66(12):1883–1891.
- 327 4. Slater HC, Ross A, Felger I, et al. The temporal dynamics and infectiousness of subpatent
- 328 Plasmodium falciparum infections in relation to parasite density. Nature Communications.
- 329 2019 Mar 29;10(1):1433.
- 330 5. Molineaux L, Gramiccia G, Organization WH. The Garki project : research on the
- epidemiology and control of malaria in the Sudan savanna of West Africa [Internet]. World
- Health Organization; 1980 [cited 2020 Feb 18]. Available from:
- 333 https://apps.who.int/iris/handle/10665/40316
- 334 6. Pathak S, Rege M, Gogtay NJ, et al. Age-Dependent Sex Bias in Clinical Malarial Disease in
- 335 Hypoendemic Regions. PLoS One [Internet]. 2012 Apr 25 [cited 2020 Feb 18];7(4).

336	7.	Landgraf B, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Parasite density of
337		Plasmodium falciparum malaria in Ghanaian schoolchildren: evidence for influence of sex
338		hormones? Transactions of the Royal Society of Tropical Medicine and Hygiene. 1994
339		Jan;88(1):73–74.
340	8.	Camargo LMA, Colletto GMDD, Ferreira MU, et al. Hypoendemic Malaria in Rondonia
341		(Brazil, Western Amazon Region): Seasonal Variation and Risk Groups in an Urban Locality.
342		The American Journal of Tropical Medicine and Hygiene. 1996 Jul 1;55(1):32–38.
343	9.	Moon JJ, Cho S-Y. Incidence patterns of vivax malaria in civilians residing in a high-risk
344		county of Kyonggi-do (Province), Republic of Korea. Korean J Parasitol. 2001
345		Dec;39(4):293–299.
346	10.	Finda MF, Moshi IR, Monroe A, et al. Linking human behaviours and malaria vector biting
347		risk in south-eastern Tanzania. PLoS One [Internet]. 2019 Jun 3 [cited 2020 Apr 8];14(6).
348	11.	Nhamoyebonde S, Leslie A. Biological Differences Between the Sexes and Susceptibility to
349		Tuberculosis. J Infect Dis. 2014 Jul 15;209(suppl_3):S100–S106.
350	12.	Bernin H, Lotter H. Sex Bias in the Outcome of Human Tropical Infectious Diseases:
351		Influence of Steroid Hormones. J Infect Dis. 2014 Jul 15;209(suppl_3):S107–S113.
352	13.	Fischer J, Jung N, Robinson N, Lehmann C. Sex differences in immune responses to
353		infectious diseases. Infection. 2015 Aug 1;43(4):399–403.

- 14. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat
  Rev Immunol. 2008 Sep;8(9):737–744.
- 356 15. Nankabirwa JI, Briggs J, Rek J, et al. Persistent Parasitemia Despite Dramatic Reduction in
- 357 Malaria Incidence After 3 Rounds of Indoor Residual Spraying in Tororo, Uganda. J Infect
- 358 Dis. 2019 Mar 15;219(7):1104–1111.
- 359 16. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
- 360 detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets.
- 361 PLoS Med. 2015 Mar;12(3):e1001788.
- 362 17. Snounou G, Viriyakosol S, Zhu XP, et al. High sensitivity of detection of human malaria
   363 parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993
   364 Oct;61(2):315–320.
- 365 18. Miller RH, Hathaway NJ, Kharabora O, et al. A deep sequencing approach to estimate
  366 Plasmodium falciparum complexity of infection (COI) and explore apical membrane
  367 antigen 1 diversity. Malar J. 2017 Dec 16;16(1):490.
- Hathaway NJ, Parobek CM, Juliano JJ, Bailey JA. SeekDeep: single-base resolution de novo
   clustering for amplicon deep sequencing. Nucleic Acids Res. 2018 Feb 28;46(4):e21–e21.
- 20. Lerch A, Koepfli C, Hofmann NE, et al. Longitudinal tracking and quantification of individual
  Plasmodium falciparum clones in complex infections. Sci Rep [Internet]. 2019 Mar 4 [cited
  2020 Feb 18];9.

373	21.	Koepfli C, Mueller I. Malaria Epidemiology at the Clone Level. Trends Parasitol. 2017

- 374 Dec;33(12):974–985.
- 375 22. Nguyen T-N, von Seidlein L, Nguyen T-V, et al. The persistence and oscillations of
- 376 submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in
- 377 Vietnam: an open cohort study. Lancet Infect Dis. 2018 May;18(5):565–572.
- 23. Koepfli C, Schoepflin S, Bretscher M, et al. How much remains undetected? Probability of
- molecular detection of human Plasmodia in the field. PLoS ONE. 2011 Apr 28;6(4):e19010.
- 380 24. Ross A, Koepfli C, Li X, et al. Estimating the numbers of malaria infections in blood samples
- using high-resolution genotyping data. PLoS ONE. 2012;7(8):e42496.
- 382 25. R Core Team. R: A language and environment for statistical computing. [Internet]. R
- 383 Foundation for Statistical Computing, Vienna, Austria.; 2019. Available from: URL
- 384 https://www.R-project.org/.
- 26. Python Language Reference, version 3.7.4. [Internet]. Python Software Foundation.;
- 386 Available from: Available at http://www.python.org
- 387 27. Rondeau V, Gonzalez JR. frailtypack: A computer program for the analysis of correlated
- 388 failure time data using penalized likelihood estimation. Computer Methods and Programs
- in Biomedicine. 2005 Nov 1;80(2):154–164.

390	28.	Rondeau V, Marzroui Y, Gonzalez JR. frailtypack: An R Package for the Analysis of
391		Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or
392		Parametrical Estimation. Journal of Statistical Software. 2012 Apr 17;47(1):1–28.
393	29.	Abdalla SI, Malik EM, Ali KM. The burden of malaria in Sudan: incidence, mortality and
394		disability – adjusted life – years. Malar J. 2007 Jul 28;6:97.
395	30.	Klein SL, Shann F, Moss WJ, Benn CS, Aaby P. RTS,S Malaria Vaccine and Increased
396		Mortality in Girls. mBio [Internet]. 2016 Apr 26 [cited 2020 Feb 18];7(2).
397	31.	Delić D, Ellinger-Ziegelbauer H, Vohr HW, Dkhil M, Al-Quraishy S, Wunderlich F.
398		Testosterone response of hepatic gene expression in female mice having acquired
399		testosterone-unresponsive immunity to Plasmodium chabaudi malaria. Steroids. 2011
400		Oct;76(10–11):1204–1212.
401	32.	Wunderlich F, Marinovski P, Benten WP, Schmitt-Wrede H.P., Mossman, H. Testosterone
402		and Other Gonadal Factor(s) Restrict the Efficacy of Genes Controlling Resistance to
403		Plasmodium Chabaudi Malaria [Internet]. Parasite immunology. 1991 [cited 2020 Feb 18].